Target antigen–displaying extracellular vesicles boost CAR T cell efficacy in cell and mouse models of neuroblastoma
Authors:
- Anna Maria GiudiceAGAnna Maria Giudice
- Sydney L. RothSRSydney L. Roth
- Guillem Pascual-PastoGPGuillem Pascual-Pasto
- Patrick M. SchürchPSPatrick M. Schürch
- Geoffrey RouinGRGeoffrey Rouin
- Brendan McIntyreBMBrendan McIntyre
- Grant P. GrothusenGGGrant P. Grothusen
- Evan Cresswell-ClayECEvan Cresswell-Clay
- David GroffDGDavid Groff
- Vincent ZecchinoVZVincent Zecchino
- 19 November 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (825) , eads4214
Abstract
Glypican-2 (GPC2) and the disialoganglioside GD2 are validated CAR T cell targets in neuroblastoma, but durable clinical responses remain limited. This modest chimeric antigen receptor T cell (CAR T cell) efficacy is in part due to suboptimal T cell persistence, antigen down-regulation, and a hostile tumor microenvironment, which includes immune cell–modulating extracellular vesicles (EVs). Neuroblastoma-derived EVs may contain CAR targets or other immunoregulatory elements that can modulate CAR T cell antitumor activity. Thus, we first profiled the surfaceome of neuroblastoma EVs and assessed their impact on both GPC2 and GD2 CAR T cell function. Neuroblastoma EVs displayed GPC2 and GD2, with minimal expression of programmed death-ligand 1 (PD-L1), and were detected in blood from tumor-bearing mice and patients. These EVs directly activated paired CAR T cells, suggesting a role for a peripheral source of CAR antigen. To exploit this therapeutically, we engineered nontumor-derived GPC2+ synthetic EVs (SyntEVs) as CAR T cell enhancers and armored them with either albumin-binding domains or GD2-binding domains. In mice harboring human neuroblastoma cell line–derived or patient-derived xenografts, serial infusion of armored SyntEVs after GPC2 CAR T cells enhanced tumor control by boosting peripheral CAR T cell persistence. Moreover, GD2-targeting SyntEVs decorated low-antigen tumor cells with GPC2, circumventing antigen down-regulation. This SyntEV platform offers a versatile system to address the therapeutic limitations of CAR T cells in solid tumors.Keywords
Funding Information
- National Cancer Institute (NCI R37 CA282041)
- National Cancer Institute (NCI K08 CA230223)
- Burroughs Wellcome Fund
- Rally Foundation
- Cancer Prevention and Research Institute of Texas (RP210154)
- Alex's Lemonade Stand Foundation ‘A’ Award
This publication has 73 references indexed in Scilit:
- The role of extracellular vesicles in cancerCell, 2023
- Extracellular vesicles engineered to bind albumin demonstrate extended circulation time and lymph node accumulation in mouse modelsJournal of Extracellular Vesicles, 2022
- GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicityCancer Cell, 2021
- Updating MISEV: Evolving the minimal requirements for studies of extracellular vesiclesJournal of Extracellular Vesicles, 2021
- Extracellular vesicles as modifiers of antibody‐drug conjugate efficacyJournal of Extracellular Vesicles, 2021
- Shedding Light on Extracellular Vesicle Biogenesis and BioengineeringAdvanced Science, 2020
- Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and MemoryCell, 2019
- Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk NeuroblastomaCancer Cell, 2017
- Assessment of programmed death‐ligand 1 expression and tumor‐associated immune cells in pediatric cancer tissuesCancer, 2017
- Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancerScience China Life Sciences, 2016